|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
PIK3CA-mutated Metastatic Breast Cancer [ESMO]
|
|
|
|
|
|
An analysis of outcomes and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer (MBC) from the SAFIR02 trial showed that patients with PIK3CA-mutated hormone receptor (HR)-positive/HER2-negative tumours have a poor outcome and resistance to chemotherapy. Patients with PIK3CA-mutated triple-negative breast cancer (TNBC) present a better overall survival (OS).
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
Are CAR T-Cell Therapies Worth the Costs? [ASH Clinical News]
|
|
|
|
|
|
There’s also been talk about academic medical centers coming together to manufacture CAR T-cell products themselves at a reduced cost, thereby cutting out the pharmaceutical companies. Although that’s possible to do in the context of a clinical trial, I’m not sure it’s a sustainable model within our current reimbursement systems.
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA,...
|
|
|
|
UK withdrawal from the EU on 31 January 2020 [EMA]
|
|
|
|
|
|
As of 1 February 2020, no one who represents the UK, or is appointed or nominated by the UK can participate in meetings of EMA’s scientific committees, working parties or the Agency’s Management Board.
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
|
6.10 POLITIQUES
|
|
|
What happens after Brexit and what could it mean for cancer? [Cancer Research UK]
|
|
|
|
|
|
The EU is bringing in new rules for how trials are run through a Clinical Trial Regulation. The changes are popular with researchers, who believe they’re a big upgrade on the current system. We want UK Government to look at becoming a part of the new system – including negotiating access to the Regulation’s new database, which will make setting up UK-EU trials safer and easier.
|
|
|
|
|
|
|
6.4 MÉDICO-ÉCO
|
|
|
|
6.8 COMMUNICATION
|
|
|